IMRX Immuneering
- 2.100
- -0.010-0.47%
- 2.101
- +0.001+0.06%
Immuneering News
Immuneering Price Target Maintained With a $13.00/Share by Chardan Capital
Immuneering Is Maintained at Buy by Chardan Capital
Immuneering Analyst Ratings
Morgan Stanley Maintains Immuneering(IMRX.US) With Hold Rating, Maintains Target Price $4
Morgan Stanley Maintains Immuneering(IMRX.US) With Hold Rating, Maintains Target Price $4
Cautious Hold Recommendation on Immuneering Amid Promising Developments and Financial Uncertainties
Needham Maintains Immuneering(IMRX.US) With Buy Rating, Maintains Target Price $15
Immuneering Analyst Ratings
Needham Reiterates Buy on Immuneering, Maintains $15 Price Target
Outperform Rating Reaffirmed for Immuneering's Stock Amidst Promising IMM-1-104 Phase 2a Study Results
Immuneering Price Target Maintained With a $15.00/Share by Needham
Immuneering Analyst Ratings
Chardan Raises Price Target on Immuneering to $13 From $12, Maintains Buy Rating
Morgan Stanley Maintains Immuneering(IMRX.US) With Hold Rating, Maintains Target Price $4
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), McKesson (MCK) and Neurocrine (NBIX)
Positive Phase 2a Trial Data Reinforces Buy Rating for Immuneering's Stock
Immuneering Analyst Ratings
Buy Rating on Immuneering: Fast-Track FDA Designation and Promising Clinical Trials Underpin Positive Outlook
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), Eli Lilly & Co (LLY) and Teva Pharmaceutical (TEVA)
Buy Rating Affirmed for Immuneering With $8 Price Target Amidst Promising Pipeline and Upcoming Data Events
Analysis
Price Target
No Data
No Data